GSK 4106647A
Alternative Names: GSK-4106647; GSK-4106647-A; HPV9-AS04Latest Information Update: 22 Oct 2024
Price :
$50 *
At a glance
- Originator Unknown
- Developer GSK
- Class Cancer vaccines; Papillomavirus vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Human papillomavirus infections
Most Recent Events
- 30 Jun 2024 Discontinued - Phase-I/II for Human papillomavirus infections (In adolescents, In children, Prevention, In adults) in United Kingdom (unspecified route) (GSK pipeline, October 2024)
- 02 Feb 2023 Phase-I/II clinical trials in Human papillomavirus infections (In adolescents, In children, Prevention, In adults) in United Kingdom (unspecified route) (GlaxoSmithKline pipeline, February 2023)
- 11 Nov 2022 Phase-I clinical trials in Human papillomavirus infections (In children, In adults, In adolescents, Prevention) in United Kingdom (unspecified route)